Rather than offer several biosimilars of blockbuster immunology drug Humira, CVS Health is planning to sell a cheaper version from its new subsidiary, Cordavis. CVS has said that this move reduces the cost of biosimilars and ensures product availability; however, insiders argue it’s a profit-driven strategy. CVS plans to sell Hyrimoz, the Humira biosimilar from Sandoz, under a Cordavis private label, with plans to launch in Q1 2024.
Open source leaders are pushing for permanent government financing to maintain open source projects. They argue that as government oversight is vital to the national